@article{5e3910b4f81b40899b7b1b2bf7a6c6aa,
title = "EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma",
abstract = "This guideline provides recommendations for diagnostic and therapeutic procedures for patients with malignant gliomas. We differentiate evidence-based standards from reasonable options or non-evidence-based measures that should no longer be considered. The recommendations herein should provide a framework and assurance for the choice of diagnostic procedures and therapeutic measures and aim to reduce complications from unnecessary treatment and cost. The guideline contributes to a critical appreciation of concurrent drugs with a focus on the controlled use of anticonvulsants and steroids. It should serve as a guideline for all professionals involved in the diagnostics and care of glioma patients and also as a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in Europe. Implementation of the recommendations summarised here will need interdisciplinary structures of care for patients with brain tumours and structured processes of diagnostic and therapeutic procedures.",
author = "Michael Weller and {van den Bent}, Martin and Kirsten Hopkins and Tonn, {J{\"o}rg C.} and Roger Stupp and Andrea Falini and Elizabeth Cohen-Jonathan-Moyal and Didier Frappaz and Roger Henriksson and Carmen Balana and Olivier Chinot and Zvi Ram and Guido Reifenberger and Riccardo Soffietti and Wolfgang Wick",
note = "Funding Information: MW has received research grants from Antisense Pharma, Bayer, Merck Serono, and Roche and honoraria for lectures or advisory boards from Antisense Pharma, Magforce, Merck Serono, MSD, and Roche. He was the principal investigator of phase 2 or phase 3 trials investigating temozolomide (MSD) in newly diagnosed anaplastic glioma and glioblastoma as well as recurrent glioblastoma and bevacizumab in glioblastoma. MvdB has received honoraria from Roche, MSD, to-BBB, MerckAg, and Abbvie, and research support from Roche and Abbvie. KH has received honoraria from Roche. JCT has received honoraria for lectures or advisory boards from Merck Serono, Medac, BrainLab, and Roche. RSt served on advisory boards of Merck KGaA, MSD, and Roche/Genentech. He is a principal investigator on trials evaluating temozolomide in low-grade glioma, and NovoTTF or cilengitide in newly diagnosed glioblastoma. EC-J-M has received honoraria for advisory boards from Merck Serono. RH is member of the steering committee of the AVAGlio study (Roche). CB has received honoraria from Roche, Merck Serono, and Novartis for lectures and advisory boards. OC is consultant for Roche and has received honoraria for advisory boards from AstraZeneca and MSD. He served as the principal investigator of the AVAGlio trial. ZR is a consultant to Novocure. GR has received a research grant from Roche and honoraria for advisory boards from Merck Serono and Roche. RSo has received grants and honoraria for lectures and advisory boards from MSD, Roche, Merck Serono, and Mundipharma. WW reports on having received consulting and lecture fees from MSD, Roche, and Magforce. WW has received research support from Apogenix, Boehringer Ingelheim, Eli Lilly, MSD, and Roche. He serves on the steering committee of the AVAglio trial involving bevacizumab in glioblastoma and has been lead investigator in glioma trials involving temozolomide, bevacizumab, enzastaurin, and APG101. AF and DF declare no competing interests. ",
year = "2014",
month = aug,
doi = "10.1016/S1470-2045(14)70011-7",
language = "English (US)",
volume = "15",
pages = "e395--e403",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "9",
}
